Ziccum AB Stock

Equities

ZICC

SE0011415595

Pharmaceuticals

Delayed Nasdaq Stockholm 07:20:13 2024-04-29 am EDT 5-day change 1st Jan Change
6.04 SEK -0.98% Intraday chart for Ziccum AB -4.73% -21.15%
Sales 2022 17K 1.56K Sales 2023 6.32M 579K Capitalization 106M 9.69M
Net income 2022 -28M -2.57M Net income 2023 -21M -1.92M EV / Sales 2022 748 x
Net cash position 2022 21.52M 1.97M Net cash position 2023 2.14M 196K EV / Sales 2023 16.4 x
P/E ratio 2022
-1.19 x
P/E ratio 2023
-4.94 x
Employees 8
Yield 2022 *
-
Yield 2023
-
Free-Float 75.57%
More Fundamentals * Assessed data
Dynamic Chart
Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace CI
Ziccum AB and project partner Zurich institute of Applied Sciences Updates LaminarPace Simulation Project Progress and Findings CI
Ziccum AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Ziccum Reports Successful Mrna/Lnp Feasibility Study with Major Biotech Corporation CI
Ziccum AB Signs Academic Collaboration with University of Copenhagen on Inhalable Mrna Vaccine Project CI
Ziccum AB Signs Agreement for Vaccine Evaluation Project with Major US Biomanufacturing Corporation CI
Ziccum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ziccum AB Reports Positive Results from External Contract Research Partner Truly Labs, Confirming High Activity Levels in Mrna/Lnp Materials Dried by Laminarpace CI
Ziccum Names New COO MT
Ziccum AB Appoints Xavier Turon as Chief Operating Officer CI
Ziccum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ziccum AB Signs Evaluation Agreement for Feasibility Study with Major Global Pharmaceutical Corporation CI
Ziccum AB Joint Proposal Not Selected for Detailed Application in Current CEPI Call CI
Ziccum Recruits Amniotics Executive as CFO, Shares Up 13% MT
Ziccum AB Appoints Johny Humaloja as CFO, Effective June 15, 2023 CI
More news
1 day-0.98%
1 week-4.73%
Current month-6.21%
1 month-4.13%
3 months-13.96%
6 months-7.08%
Current year-21.15%
More quotes
1 week
5.76
Extreme 5.76
6.66
1 month
5.50
Extreme 5.5
6.66
Current year
5.50
Extreme 5.5
8.26
1 year
3.34
Extreme 3.34
9.90
3 years
1.70
Extreme 1.7
26.30
5 years
1.70
Extreme 1.7
35.40
10 years
1.70
Extreme 1.7
35.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 22-05-08
Director of Finance/CFO 58 23-06-14
Chairman 44 17-04-04
Members of the board TitleAgeSince
Chairman 44 17-04-04
Director/Board Member - -
Director/Board Member 44 21-04-26
More insiders
Date Price Change Volume
24-04-29 6.04 -0.98% 3 869
24-04-26 6.1 -2.56% 6,962
24-04-25 6.26 -4.28% 13,094
24-04-24 6.54 +3.81% 21,267
24-04-23 6.3 -0.63% 1,532

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 07:20 am EDT

More quotes
Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.
More about the company